raf...IMO the mandate of the FDA is 50% to make sure that the drug doesn't hurt people and 50% that the drug actually helps people..Vascepa has already passed the first 50% test with Reduce-It and is well on its way to passing the second 50% test with on going studies in Canada, Argentina, and California(the study in Canada having been reported by Dr, Bhatt in late breaking news at the NLA meeting)...we already know that proven safe Vascepa reduces the incidence of CVD...and there is sufficient reason accruing from science and studies to believe that it will reduce the incidence of CVD in patients infected with Covid... Amarin should have already applied to the FDA for approval of Vascepa as a treatment for Covid...and if not, it should apply ASAP.